Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 4/20 | 0.62 |
| ▸ | HTR2A | P28223 | 5/20 | 0.49 |
| ▸ | KIF11 | P52732 | 4/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.48 |
| ▸ | HTR2C | P28335 | 4/20 | 0.47 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6236968 | 0.87 | MAPKAPK2 (0.81) | MAPKAPK2SIRT1 | |
| SCHEMBL1657649 | 0.87 | MAPKAPK2 (0.73) | MAPKAPK2HTR2AKIF11TRPV1HTR2C | |
| SCHEMBL6238198 | 0.82 | MAPKAPK2 (0.63) | MAPKAPK2 | |
| SCHEMBL9686470 | 0.81 | MAPKAPK2 (0.53) | MAPKAPK2HTR2A | |
| SCHEMBL1658785 | 0.77 | MAPKAPK2 (1.00) | MAPKAPK2SIRT1 | |
| SCHEMBL6235510 | 0.76 | MAPKAPK2 (0.81) | MAPKAPK2SIRT1 | |
| SCHEMBL6243057 | 0.74 | MAPKAPK2 (0.65) | MAPKAPK2KIF11SIRT1 | |
| SCHEMBL6236811 | 0.73 | MAPKAPK2 (0.64) | MAPKAPK2SIRT1 | |
| SCHEMBL947568 | 0.73 | TRPV1 (0.49) | MAPKAPK2HTR2AKIF11TRPV1HTR2C | |
| SCHEMBL6238355 | 0.72 | MAPKAPK2 (0.64) | MAPKAPK2HTR2ATRPV1HTR2CSIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050137220-A1 | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors | PHARMACIA CORPORATION (US) | 2005-06-23 | — | — | US | disclosed |
| WO-2005009370-A2 | BETA-CARBOLINE COMPOUNDS AND ANALOGUES THEREOF AND THEIR USE AS MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITORS | PHARMACIA CORPORATION (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137220-A1 | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors | MAPKAPK2, MAP4K2, MAP3K2 | MAPKAPK2 1/4885HTR2A 1004/4885KIF11 801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.